The Triple-Agonist Frontier: Inside Eli Lilly’s Retatrutide and the Next Generation of Obesity Therapeutics
Executive Overview The landscape of metabolic medicine is undergoing a seismic shift, moving beyond single-hormone interventions into a new era of multi-target therapeutics. At the forefront of this pharmaceutical evolution is retatrutide, an investigational "triple-agonist" molecule developed by pharmaceutical giant Eli Lilly. Designed to activate three distinct metabolic receptors simultaneously—glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1…
